P/E ratio for Regulus Therapeutics (RGLS)
P/E ratio as of April 2024 (TTM): -1.36
According to Regulus Therapeutics's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -1.36095. At the end of 2022 the company had a P/E ratio of -0.7366.
P/E ratio history for Regulus Therapeutics from 2012 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | -0.7366 | -24.73% |
| 2021 | -0.9786 | -60.13% |
| 2020 | -2.45 | 203.37% |
| 2019 | -0.8091 | 387.19% |
| 2018 | -0.1661 | -82.34% |
| 2017 | -0.9405 | -35.21% |
| 2016 | -1.45 | -81.85% |
| 2015 | -8.00 | -36.16% |
| 2014 | -12.5 | -15.21% |
| 2013 | -14.8 | 9286.92% |
| 2012 | -0.1575 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Sanofi SNY | 14.9 | -1,196.08% | 🇫🇷 France |
 Biogen BIIB | 10.6 | -875.96% | 🇺🇸 USA |
 Bristol-Myers Squibb BMY | 12.4 | -1,012.92% | 🇺🇸 USA |
 AstraZeneca AZN | 35.5 | -2,709.30% | 🇬🇧 UK |
 GlaxoSmithKline GSK | 11.7 | -959.10% | 🇬🇧 UK |
 Sangamo Therapeutics
SGMO | -0.3889 | -71.43% | 🇺🇸 USA |
 Dicerna Pharmaceuticals DRNA | N/A | N/A | 🇺🇸 USA |
 Alnylam Pharmaceuticals
ALNY | -36.4 | 2,574.71% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.